Navigation Links
Zogenix Reports FDA Provides New PDUFA Date for Sumavel(TM) DosePro(TM)
Date:2/18/2009

SAN DIEGO, Feb. 18 /PRNewswire/ -- Zogenix, Inc. ("Zogenix"), a private, specialty pharmaceutical company, announced that the U.S. Food & Drug Administration (FDA) has provided a target date of July 15, 2009 for completion of its review of the NDA for Sumavel DosePro (sumatriptan injection) needle-free delivery system. Zogenix is seeking marketing approval of Sumavel DosePro for the acute treatment of migraine attacks with or without aura, and the acute treatment of cluster headache episodes.

In October, the company received a Complete Response letter from the FDA citing the need for a single additional in vitro test to be conducted. Zogenix recently submitted this information to the FDA. The FDA has accepted this resubmission as a complete response, providing the new Prescription Drug User Fee Act (PDUFA) review date of July 15, 2009.

Sumavel DosePro uses the novel, proprietary DosePro drug delivery system to subcutaneously administer sumatriptan, a medication that has been used to treat migraines effectively and safely for over fifteen years, but without many of the issues associated with needle delivery. Sumavel DosePro has the potential of offering migraine relief beginning in as little as ten minutes, in a system sufferers can self administer in three easy steps. Given the unique attributes of Sumavel DosePro, Zogenix believes it has the potential to be used as a replacement for needle-based injectable forms of sumatriptan, as well as to replace tablet and nasal spray triptans for challenging migraine episodes.

Migraine affects approximately 30 million people in the United States. Patients suffer with extreme pain, nausea, vomiting, and sensitivity to light and sound, making it difficult to undertake work or other activities. Because of this, speed of relief is a key attribute identified by migraine patients when choosing a medication.

"We look forward to working w
'/>"/>

SOURCE Zogenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
2. Gentiva Reports Fourth Quarter and Fiscal 2008 Results
3. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
4. Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009
5. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
6. YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
7. Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results
8. Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
9. Corgenix Reports Second Quarter Fiscal 2009 Financial Results
10. Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009.
11. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- Xybion Corporation, the ... global corporations operating in highly regulated industries, announced ... annual Global User Group Conference, Xybion International Exchange, ... Philadelphia, Pennsylvania at the Sheraton Society ... This year,s conference theme ...
(Date:7/25/2014)... BEIJING , July 25, 2014 Sinovac Biotech ... biopharmaceutical products in China , today announced ... second quarter ended June 30, 2014, after market close on ... conference call prior to the market opening on Friday, August ... at 8:00 p.m. China Standard Time) to review the Company,s ...
(Date:7/24/2014)... RIDGE, Tenn., July 24, 2014 -- A novel combination ... the Department of Energy,s Oak Ridge National Laboratory an ... for its unusual physical and electrochemical properties. , ... how oxygen affects the surface of a perovskite manganite, ... behavior. The new avenue to understand surface behavior could ...
(Date:7/24/2014)... , July 24, 2014  Now available is ... home. Rehealth Regenerative Therapies , located in ... other physically active people a new health option: ... Regardless of age, countless patients suffer from joint and ... such as muscle tears, torn rotator cuff, tennis elbow, ...
Breaking Biology Technology:Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2ORNL study reveals new characteristics of complex oxide surfaces 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... , ... announced that its Oragene®•DNA product has been selected by Prometheus as the sample collection ... for this type of genetic testing service as it solves sample collection challenges inherent ... ...
... SUNRISE, Fla., Aug. 18 Bioheart, Inc., (OTC ... and biologics that help monitor, diagnose and treat heart failure ... Directors have joined the Company,s executive management team. In addition ... of Directors, Karl E. Groth, Ph.D., became the Chief Executive ...
... , , BOSTON, Aug. 18 ... is pleased to host their September Congress taking place at the ... economic climate, with heightened M & A activity in the pharma ... governance has become more critical," says Sharon Langan, Senior Program Manager, ...
Cached Biology Technology:DNA Genotek Sample Collection Kit Selected by Prometheus for MyCeliacID™ Genetic Test 2DNA Genotek Sample Collection Kit Selected by Prometheus for MyCeliacID™ Genetic Test 3Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry 2Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry 3Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry 4Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry 5Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry 6Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry 7CBI Hosts 5th Annual Pharma/Biotech Enterprise Governance, Risk and Controls Congress 2
(Date:7/28/2014)... virus killers to prevent and treat HIV infection has ... response these molecules can arouse as they get rid ... at the Weizmann Institute and the National Institutes of ... these molecules interferons around the time of ... the disease. Their research appeared in Nature . ...
(Date:7/28/2014)... Researchers using statistical tools to map social connections ... traditional observational techniques, shedding light on prairie dog ... bubonic plague and guide future conservation efforts. The ... State University and the National Evolutionary Synthesis Center ... are subject to bubonic plague," says Dr. Jennifer ...
(Date:7/27/2014)... survived the asteroid strike that wiped them out if ... history, scientists say. , A fresh study using up-to-date ... to build a new narrative of the prehistoric creatures, ... that in the few million years before a 10km-wide ... environmental upheaval. This included extensive volcanic activity, changing sea ...
Breaking Biology News(10 mins):Interfering with interferon 2Social network research may boost prairie dog conservation efforts 2Dinosaurs fell victim to perfect storm of events, study shows 2
... of researchers coordinated by ornithologist Bret Whitney of the LSU ... of birds previously unknown to science. The formal description of ... the "Handbook of the Birds of the World" series. Not ... introduced under a single cover, and all 15 discoveries involve ...
... Researchers have created a model that may explain the complexities ... the Journal of the Royal Society Interface , offers ... modern "genetic code." "Our model shows that today,s genetic ... random chance," explained Justin Jee, a doctoral student at NYU ...
... Tuesday, August 27: The radioactive ocean plume from the 2011 ... US within three years from the date of the incident ... in the journal Deep-Sea Research 1 ., While atmospheric ... of the incident, the radioactive particles in the ocean plume ...
Cached Biology News:LSU research responsible for naming 15 new species of Amazonian birds 2Researchers develop model of 'near-optimal' genetic code 2Fukushima radioactive plume to reach US in 3 years 2
The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system....
... The PROTEAN II xi multi-cell is for 2-D ... efficient cooling capabilities. The PROTEAN II xi multi-cell ... comb, type of glass plates, and cooling system. ... converted to the PROTEAN II XL multi-cell for ...
... II xi cell, 16 cm, is used for ... proteins in agarose gels. The cell is supplied ... central cooling core with gaskets, lower buffer chamber, ... 4 sandwich clamps, upper buffer dam, casting stand ...
CleanCut agarose is used to prepare genomic DNA plugs for use in pulsed field gel electrophoresis (PFGE) applications. Supplied as a 12 ml solution of 2% agarose....
Biology Products: